Open access
Oct 2026
161Tb Radiopharmaceutical Therapy as a Treatment for RANKL-Positive Multiple Myeloma.
Findings support 161Tb as a next-generation theranostic radionuclide for RANKL-positive malignancies and provide a strong rationale for clinical translation, highlighting the value of repurposing a clinically established antibody for radiopharmaceutical therapy.
Hao-Yi Yan, Jun Li, Chuan-Mian Xu et al.
· European Journal of Pharmace... · 0 citations